Glucagon-like peptide-1 (GLP-1) agonists are a class of medications utilized to treat type 2 diabetes mellitus (T2DM) and obesity. As a class of medications, they are among several pharmacological options for these endocrine diseases. The function of GLP-1 agonists is to lower serum glucose levels and thereby manage metabolism in affected patients. Participating clinicians gain an enhanced understanding of when to prescribe these agonists, consider specific patient populations, and seek consultations with specialists in the care of their patients. Recent recommendations regarding mixed formulations are also included in alignment with current research on this drug class. This activity will highlight the indications, mechanism of action, administration, adverse effect profile, and contraindications for these drugs. An interprofessional team of nurses, primary care clinicians, pharmacists, and endocrinologists remains pertinent to care for patients prescribed this class of medications.
Copyright © 2025, StatPearls Publishing LLC.